GlassScriptPhysician profile
Vivienne Taylor
NPI 1861464372
$1,192.50
in general payments reported to CMS, 2019-2025
21 companies · $687 in 2025
The $687 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.56 · 2022: $113 · 2023: $80.11 · 2024: $237 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $222.75 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $160.68 | 2021-2025 | |
| Madrigal Pharmaceuticals | $108.39 | 2025 | Rezdiffra |
| Novo Nordisk INC | $74.35 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $67.08 | 2025 | Breztri, Airsupra |
| Gilead Sciences, INC. | $62.28 | 2024 | |
| Indivior INC. | $51.88 | 2023-2024 | Sublocade |
| Exact Sciences Corporation | $51.67 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $48.05 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Dexcom, INC. | $47.71 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $44.00 | 2023-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.00 | 2022 | |
| Lilly USA, LLC | $41.13 | 2024-2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $31.36 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $29.91 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.87 | 2025 | Auvelity |
| Amgen INC. | $20.17 | 2022 | |
| Grifols USA, LLC | $19.51 | 2024 | Prolastin-C Liquid |
| Vertex Pharmaceuticals Incorporated | $15.82 | 2025 | |
| Genentech USA, INC. | $15.20 | 2022 | |
| Sanofi Pasteur INC. | $13.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivienne Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.